Do epigenetic drug treatments hold the key to killing cancer progenitor cells?

Epigenomics

Volumn 6, Issue 2, 2014, Pages 161-165

  Byler, Shannon ^a   Sarkar, Sibaji ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; drug; epigenetics; progenitor; resistance

Indexed keywords

DNA;

ADULT STEM CELL; CANCER CONTROL; CANCER GENETICS; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL KILLING; CELL REGENERATION; DNA METHYLATION; EDITORIAL; EMBRYONIC STEM CELL; EPIGENETICS; HUMAN; NONHUMAN; ONCOGENE C MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RECURRENT DISEASE; STEM CELL; CELL DIFFERENTIATION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PATHOLOGY;

CELL DIFFERENTIATION; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84900403807     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.4     Document Type: Editorial

References (25)

1. Gil J, Stembalska A, Pesz KA, Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. J. App. Genet. 49(2), 193-199 (2008). (Pubitemid 351873043)
2. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells and cancer. Stem Cells 25(3), 707-711 (2007). (Pubitemid 46354230)
3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006). (Pubitemid 44233629)
4. Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and reexpression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5 (1 )87-94 (2013).
5. Sarkar S, Horn G, Moulton K et al. Cancer development, progression, and therapy: an epigenetic overview. Int. J. Mol. Sci. 14, 21087-21113 (2013).
6. Lukasz J, Aksoy FB, Hersi HM, Wantuch S, Sawado T. Identifying division symmetry of mouse embryonic stem cells: negative impact of DNA methyltransferases on symmetric self-renewal. Stem Cell Rep. 1, 360-369 (2013).
7. Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult gliobalstoma multiform. Oncogene 23, 9392-9400 (2004). (Pubitemid 40069671)
8. Lee J, Choi JH, Joo CK. TGF-β1 regulates cell fate during epithelial-mesenchymal transition by upregulating survivin. Cell Death Dis. 4, e714 (2013).
9. Matsumura N, Huang Z, Mori S et al. Epignetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 21, 74-82 (2011).
10. Wong A, Lee S. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012, 1-13 (2012).
11. Byler S, Goldgar S, Heerboth S.Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res.34(3)1071-1077 (2014).
12. Chaffer C, Brueckmann I Scheel. C et al. Normal and neoplastic nonstem cells can spontaneously covert to a stem-like state. Proc. Natl Acad. Sci. USA 108(19), 7950-7955 (2011).
13. Mataga M, Rosenthal S, Heerboth S et al. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitors. Anticancer Res. 32, 2523-2530 (2012).
14. Housman G, Mataga AM, Devalapalli A et al. Demethylation and re-expression of tumor suppressor genes by HDAC inhibitors and calpain inhibitors in cancer cells: a study related to synergistic type growth inhibition and reduction of motility. Presented at: The Epigenetics World Congress. MA, USA, 26-27 April 2011 (Abstract 206).
15. Sarkar S, Faller DV. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 21(1), 47-53 (2011).
16. Frew AJ, Lindemann RK Martin. BP et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl Acad. Sci. USA 105(32), 11317-11322 (2008).
17. Juergens R, Wrangle J Vendetti. F et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598-607 (2011).
18. Johannessen CM, Johnson LA, Piccioni F et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504(7478), 138-142 (2013).
19. Radpour R, Barekati Z, Kohler C et al. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS ONE 6, e27355 (2011).
20. Yang X, Ferguson AT, Nass SJ et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60, 6370-6394 (2000).
21. Hanahan D, Weinber RA. The hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
22. Fearon ER, Volgelstein B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
23. Volgelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004). (Pubitemid 39070849)
24. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
25. Sarkar S, Longacre M, Tatur N, Heerboth S, Lapinska K. Histone deacetylases (HDACs): function, mechanism, and inhibition. In:Encyclopedia of Analytical Chemistry 2014. Meyers RA (Ed.): John Wiley and Sons, Chichester, UK, (2014) doi:10.1002/9780470027318.a9365 (Epub ahead of print).